D
Daniel Heinrich
Researcher at Akershus University Hospital
Publications - 42
Citations - 2029
Daniel Heinrich is an academic researcher from Akershus University Hospital. The author has contributed to research in topics: Prostate cancer & Radium-223. The author has an hindex of 17, co-authored 42 publications receiving 1583 citations. Previous affiliations of Daniel Heinrich include University of Oslo.
Papers
More filters
Journal ArticleDOI
Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial
Oliver Sartor,Robert E. Coleman,Sten Nilsson,Daniel Heinrich,Svein Inge Helle,Joe M. O'Sullivan,Sophie D. Fosså,Ales Chodacki,Paweł Wiechno,John P Logue,Anders Widmark,Dag Clement Johannessen,Peter Hoskin,Nicholas D. James,Arne Solberg,Isabel Syndikus,Nicholas J. Vogelzang,C. Gillies O'Bryan-Tear,M. Shan,Øyvind S. Bruland,Chris Parker +20 more
TL;DR: Radium-223 treatment did not seem to significantly reduce the risk of symptomatic pathological bone fracture, or the need for tumour-related orthopaedic surgical intervention, but should be considered as a treatment option for patients with castration-resistant prostate cancer and symptomatic bone metastases.
Journal ArticleDOI
Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019[Formula presented]
Silke Gillessen,Gerhardt Attard,Tomasz M. Beer,Himisha Beltran,Anders Bjartell,Alberto Bossi,Alberto Briganti,Robert G. Bristow,Kim N. Chi,Noel W. Clarke,Ian D. Davis,Johann S. de Bono,Charles G. Drake,Ignacio Duran,Ros Eeles,Eleni Efstathiou,Christopher P. Evans,Stefano Fanti,Felix Y. Feng,Karim Fizazi,Mark Frydenberg,Martin E. Gleave,Susan Halabi,Axel Heidenreich,Axel Heidenreich,Daniel Heinrich,Celestia S. Higano,Celestia S. Higano,Michael S Hofman,Michael S Hofman,Maha Hussain,Nicolas James,Ravindran Kanesvaran,Philip W. Kantoff,Philip W. Kantoff,Raja B. Khauli,Raya Leibowitz,Chris Logothetis,Chris Logothetis,Fernando C. Maluf,Robin Millman,Alicia K. Morgans,Michael J. Morris,Nicolas Mottet,Hind Mrabti,Declan G. Murphy,Declan G. Murphy,Vedang Murthy,William Oh,Piet Ost,Joe M. O'Sullivan,Joe M. O'Sullivan,Anwar R. Padhani,Chris Parker,Darren M.C. Poon,Colin C. Pritchard,Robert E. Reiter,Mack Roach,Mark A. Rubin,Charles J. Ryan,Fred Saad,Juan Pablo Sade,Oliver Sartor,Howard I. Scher,Howard I. Scher,Neal D. Shore,Eric J. Small,Matthew R. Smith,Howard R. Soule,Cora N. Sternberg,Thomas Steuber,Hiroyoshi Suzuki,Christopher Sweeney,Matthew R. Sydes,Mary-Ellen Taplin,Bertrand Tombal,Levent Türkeri,Inge M. van Oort,Almudena Zapatero,Aurelius Omlin,Aurelius Omlin +80 more
TL;DR: These voting results from a panel of prostate cancer experts can help clinicians and patients navigate controversial areas of advanced prostate management for which high-level evidence is sparse and provide a practical guide to help clinicians discuss therapeutic options with patients.
Journal ArticleDOI
Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial
Fred Saad,Joan Carles,Silke Gillessen,Axel Heidenreich,Daniel Heinrich,Jeremy Gratt,Jeremy Levy,Kurt Miller,Sten Nilsson,Oana Petrenciuc,Marcello Tucci,Manfred P. Wirth,Judith Federhofer,Joe M. O'Sullivan +13 more
TL;DR: This study investigated safety and overall survival in radium-223 treated patients in an early access programme done after the ALSYMPCA study and before regulatory approval of radia-223, an international, prospective, interventional, open-label, single-arm, phase 3b study.
Journal ArticleDOI
Overall Survival Benefit of Radium-223 Chloride (Alpharadin™) in the Treatment of Patients with Symptomatic Bone Metastases in Castration-resistant Prostate Cancer (CRPC): a Phase III Randomized Trial (ALSYMPCA)
Chris Parker,Daniel Heinrich,Joe M. O'Sullivan,Sophie D. Fosså,Ales Chodacki,T. Demkow,A. Cross,B. Bolstad,J. Garcia-Vargas,Oliver Sartor +9 more
Journal ArticleDOI
An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223.
Oliver Sartor,Robert E. Coleman,Sten Nilsson,Daniel Heinrich,Svein Inge Helle,Joe M. O'Sullivan,Nicholas J. Vogelzang,Oø Bruland,S. Kobina,Scott Wilhelm,L. Xu,M. Shan,Michael W. Kattan,Chris Parker +13 more
TL;DR: TALP or LDH declines at 12 weeks correlated with longer OS, but did not meet statistical surrogacy requirements, and dynamic changes in tALP and LDH during radium-223 treatments may be useful to monitor, but do not serve as surrogates for survival.